Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Pharmaceuticals Inc.

www.vrtx.com

Latest From Vertex Pharmaceuticals Inc.

Start-Up Quarterly Statistics: Financings Fell 17% To $2.84bn In Q2

A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.

Deals Financing

Another No For Vertex As Scotland Rejects Offer For Orkambi And Symkevi

The Scottish Medicines Consortium has issues over the price Vertex Pharmaceuticals is asking for its cystic fibrosis drugs, and like NICE in England it has rejected the products for use on the National Health Service.

 

United Kingdom Cost Effectiveness

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

Vertex' Dueling Phase III Programs Pay Off In NDA Submission Speed

Next-generation CFTR corrector elexacaftor aims to be first cystic fibrosis product with minimal function mutations claim after winning out over VX-659 thanks to tolerability advantage in dueling Phase III programs testing combination with the components of Vertex’ Symdeko.

Respiratory Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vertex Pharmaceuticals Inc.
  • Senior Management
  • Jeffrey Leiden, MD, PhD, Chmn., Pres. & CEO
    Charles F Wagner, EVP, CFO
    Stuart A Arbuckle, EVP, Chief Commercial Officer
    David Altshuler, MD, PhD, EVP, Global Research & CSO
    Reshma Kewalramani, MD, EVP, Global Medicines Dev. & Medical Affairs & CMO
  • Contact Info
  • Vertex Pharmaceuticals Inc.
    Phone: (617) 444-6100
    50 Northern Ave.
    Boston, MA 02210
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register